UCB's Cimzia receives complete response letter for rheumatoid arthritis
This article was originally published in Scrip
Executive Summary
The US FDAhas issued UCBwith a complete response for its anti-TNF product Cimzia (certolizumab pegol), for the additional indication of rheumatoid arthritis.